| CAS NO: | 10238-21-8 |
| 规格: | ≥98% |
| 包装 | 价格(元) |
| 1g | 电议 |
| 2g | 电议 |
| 5g | 电议 |
| 10g | 电议 |
| 50g | 电议 |
| 100g | 电议 |
| Molecular Weight (MW) | 494 |
|---|---|
| Formula | C23H28ClN3O5S |
| CAS No. | 10238-21-8 |
| Storage | -20℃ for 3 years in powder form |
| -80℃ for 2 years in solvent | |
| Solubility (In vitro) | DMSO: 99 mg/mL (200.4 mM) |
| Water:<1 mg/mL | |
| Ethanol:<1 mg/mL | |
| Other info | Chemical Name: 5-chloro-N-[2-[4-(cyclohexylcarbamoylsulfamoyl)phenyl]ethyl]-2-methoxybenzamide InChi Key: ZNNLBTZKUZBEKO-UHFFFAOYSA-N InChi Code: InChI=1S/C23H28ClN3O5S/c1-32-21-12-9-17(24)15-20(21)22(28)25-14-13-16-7-10-19(11-8-16)33(30,31)27-23(29)26-18-5-3-2-4-6-18/h7-12,15,18H,2-6,13-14H2,1H3,(H,25,28)(H2,26,27,29) SMILES Code: COC1=C(C=C(C=C1)Cl)C(=O)NCCC2=CC=C(C=C2)S(=O)(=O)NC(=O)NC3CCCCC3 |
| Synonyms | HB-420; Glyburide; Glibenclamide; HB419; HB420; Micronase; Diabeta; Maninil; Micronase; Neogluconin |
| In Vitro | In vitro activity: Glyburide (0.03 mM), a sulfonylurea which has been shown to block the ATP-modulated potassium channel in insulin-secreting cells, causes concentration-dependent shifts to the right (up to 100-fold) of the IC50 value for BRL 34915 and diazoxide, and at 1 μM, abolishes the relaxation response to minoxidil sulfate. Glyburide increases the apparent affinity of HDL binding to Scavenger receptor class B type I (SR-BI). Glyburide blocks SR-BI-mediated selective lipid uptake and efflux at a potency similar to that for its inhibition of ABCA1 (IC50 approximately 275-300 mM). Glyburide (6 mM) which reduces the opening of KATP channels, aggravates Ca2+ loading only when applied to dinitrophenol-pretreated myocytes but not when applied with dinitrophenol treatment. Glyburide (10-500 nM) produces a dose-dependent inhibition of the potassium channel openers (PCOs) relaxation time course. Glyburide also reverses existing Pinacidil relaxation regardless of the degree of pre-existing relaxation. Glyburideis is able to produce its blockade regardless of the state of K+ channel activation. |
|---|---|
| In Vivo | Glyburide (GLY) dose-dependently increases urinary Na+ excretion with little change in urinary K+ excretion after i.p. administration (10-100 mg/kg) in saline-loaded conscious rats. Glyburide (25 mg/kg i.v.) increases Na+ excretion 350% during the first hour post-treatment without affecting K+ excretion, glomerular filtration rate, mean arterial pressure or heart rate. |
| Animal model | Rats |
| Formulation & Dosage | 25 mg/kg i.v. |
| References | J Pharmacol Exp Ther. 1989 Jan;248(1):149-56; J Pharmacol Exp Ther. 1993 May;265(2):933-7. |
